IDDF2023-ABS-0072 High Prevalence of Hepatic Steatosis and Fibrosis among Patients with Type 2 Diabetes Mellitus: a Prospective Community-Based Study
Xiaolong Qi,Ruiling He,Chuan Liu,Chao Sun,Dengxiang Liu,Yan Wang,Tong Dang,Rong Zhang,Jing Du,Yanan Han,Fang Li,Xuanzhe Zhang,Chengyu Liu,Xing Liu,Xiaomei Wang,Jing Wang,Xianmei Meng,Jing Hu,Jinpeng Hu,XiaoLin Lan,Jiaojian Lv,Chuxiao Shao,Ling Li,Zhihui Li,Gaojun Teng
DOI: https://doi.org/10.1136/gutjnl-2023-iddf.129
2023-01-01
Abstract:Background Chronic liver diseases and type 2 diabetes mellitus (T2DM) frequently coexist and impact synergistically, and T2DM may be one of the strongest risk factors for non-alcoholic steatosis to advanced fibrosis. We aimed to investigate the prevalence of hepatic steatosis and fibrosis, and identify risk factors associated with compensated advanced chronic liver diseases (cACLD) among Chinese adults with T2DM in the community. Methods This is a prospective, large-scale, community-based study recruiting registered adults with T2DM in six cities in China between June 2021 and November 2022. The baseline demographics, comorbidities, and vibration-controlled transient elastography-defined hepatic steatosis and fibrosis, in terms of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), were collected for analysis. Results A total of 3,196 patients with T2DM in the community (age: 65±9 years; body mass index: 24.7±3.3 kg/m2) were included in the study. The prevalence of steatosis (CAP ≥248 dB/m) and cACLD (LSM ≥10 kPa) was 60% and 9%, respectively. Additionally, 12%, 7%, 7%, and 3% of patients had mild (F1), moderate (F2), severe (F3) fibrosis, and cirrhosis (F4), respectively. The distribution of mild (S1), moderate (S2), and severe (S3) steatosis was 14%, 8%, and 38%, respectively (IDDF2023-ABS-0072 Figure 1. Proportion of patients with T2DM screened in community having liver diseases (A) Proportion of subjects having NAFLD and cACLD (B) severity of fibrosis in subjects (C) Severity of S). Furthermore, 5% of patients with non-obesity (body mass index 50 years, body mass index, and the presence of hypertension were independent predictors of cACLD among patients with T2DM in the community. Conclusions We found a considerable prevalence of hepatic steatosis and fibrosis in community patients with T2DM. It is imperative to carry out screening to promote further intervention of T2DM patients.